Indeed, no benign cells but only malignant ones and especially CSCs expose GRP78 on their surface [28,29], so that specific anti-GRP78 antibodies (and conjugates of such antibodies to antitumor agents) can selectively target breast cancer cells without affecting normal tissues. Here, HSPA5 is linked to breast carcinoma.